Tareq Abadl: Irradiated Blood – Safer, Not More Dangerous
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Irradiated Blood – Safer, Not More Dangerous.
Did you know that some blood units are actually irradiated before transfusion… not to harm, but to protect the patient?
What Does ‘Irradiated Blood’ Mean?
When we say a blood unit is irradiated, it means it has been exposed to controlled radiation to inactivate donor T lymphocytes.
Important:
Nothing ‘toxic’ is added to the blood — this is purely a safety modification.
Why Is Irradiation Needed?
The goal is to prevent a rare but serious complication:
Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD)
This happens when:
- Viable donor T cells attack the recipient’s tissues
- Leading to severe, often fatal immune reactions
According to the AABB, irradiation is used to stop donor T cells from proliferating, eliminating this risk.
Which Blood Components Are Irradiated?
Irradiation is mainly used for cellular components, such as:
- Red Blood Cells (RBCs)
- Platelets
Plasma is not irradiated (it doesn’t contain viable lymphocytes).
Beyond ABO and Rh – Smarter Blood Banking
Modern transfusion medicine is not just about matching blood groups:
Blood banks also select specialized products based on patient needs, including:
- Irradiated components
- Washed red cells
- CMV-seronegative units
As highlighted by Canadian Blood Services, these modifications help reduce transfusion-related risks in specific clinical situations.
Does Irradiation Affect the Blood Itself?
Yes – and this is clinically important:
- Reduced shelf life
- Increased potassium levels
- Structural/biochemical changes in cells
Recent updates from AABB emphasize that irradiated products are used only when clearly indicated because of these effects.
Bottom Line
Irradiated blood is not ‘dangerous blood’ – it’s safer blood for the right patient.
In transfusion medicine:
It’s not just about giving blood…
It’s about giving the right product, to the right patient, at the right time.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal